Skip to main content

Advertisement

SpringerLink
Log in

Carcinoma of unknown primary site: development in a single institution of a prognostic model based on clinical and serum variables

  • Research Articles
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Purpose

To identify clinical and biologic variables with significant impact on survival in patients with carcinomas of an unknown primary site (CUP) and to develop a simple prognostic model.

Patients and methods

In this retrospective study, univariate and multivariate prognostic factors analyses were conducted in a population of 100 patients with CUP. Patients with features requiring well defined treatments had previously been excluded.

Results

Overall survival (OS) was significantly related to the following pretreatment adverse prognostic clinical factors: a poor performance status (2 or 3), weight loss more than 10% in the last six months, the presence of liver metastases and more than two metastatic sites. Two biological parameters predicted a significantly shorter survival: elevated serum levels of alkaline phosphatase and of lactate dehydrogenase. In the multivariate analysis, only two independent adverse prognostic parameters were retained: a poor performance status and the presence of liver metastases. We developed a prognostic model for OS based on the following subgroups: good prognosis (PS 0 or 1 and absence of liver metastases), intermediate prognosis (PS≥2 or presence of liver metastases) and poor prognosis (PS≥2 or presence of liver metastases). Median OS for the three groups was 10.8, 4 and 1.9 months respectively, p<0.0001.

Conclusion

A simple prognostic model using performance status and presence of liver metastases was developed. It allowed the assignment of patients into three subgroups with different outcomes. Treatment strategies could be adapted for each subgroup. We think that this prognostic model could be useful and should be validated in other patient series.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Muir C (1995) Cancer of unknown primary site. Cancer 75:353

    Article  PubMed  CAS  Google Scholar 

  2. Pavlidis N, Briasoulis E, Hainsworth J et al (2003) Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 39:1990

    Article  PubMed  CAS  Google Scholar 

  3. Hainsworth JD, Greco FA (1993) Treatment of patients with cancer of an unknown primary site. N Engl J Med 329:257–263

    Article  PubMed  CAS  Google Scholar 

  4. Sporn JR, Greenberg BR (1993) Empirical chemotherapy for adenocarcinoma of unknown primary site. Semin Oncol 20:261–267

    PubMed  CAS  Google Scholar 

  5. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481

    Article  Google Scholar 

  6. Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163–167

    PubMed  CAS  Google Scholar 

  7. Daugaard G (1994) Unknown primary tumours. Cancer Treat Rev 20:119–147

    Article  PubMed  CAS  Google Scholar 

  8. Kambhu SA, Kelsen DP, Fiore J et al (1990) Metastatic adenocarcinomas of unknown primary site: prognostic variables and treatment results. Am J Clin Oncol 13:55–60

    Article  PubMed  CAS  Google Scholar 

  9. Hainsworth JD, Johnson DH, Greco FA (1992) Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. J Clin Oncol 10:912–922

    PubMed  CAS  Google Scholar 

  10. Abbruzzese JL, Abbruzzese MC, Hess KR et al (1994) Unknown primary carcinoma: natural history and prognostic factors in 657 patients. J Clin Oncol 12:1272–1280

    PubMed  CAS  Google Scholar 

  11. Van der Gaast A, Verweij J, Planting AST et al (1995) Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site. J Clin Oncol 13:1720–1725

    PubMed  Google Scholar 

  12. Culine S, Kramar A, Saghatchian M et al (2002) Development of a prognostic model to predict the length of survival inpatients with carcinomas of an unknown primary site. J Clin Oncol 20:4679–4683

    Article  PubMed  Google Scholar 

  13. Hess KR, Abbruzzese MC, Lenzi R et al (1999) Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res 5:3403–3410

    PubMed  CAS  Google Scholar 

  14. Culine S, Fabbro M, Ychou Y et al (1999) Chemotherapy in carcinomas of unknown primary site: A high-dose intensity police. Ann Oncol 10:569–575

    Article  PubMed  CAS  Google Scholar 

  15. Culine S, Fabbro M, Ychou Y et al (2002) Alternatively bimonthly cycles of doxorubicin, cyclophosphamide, and etoposide, cisplatin with hematopoietic growth factor support in patients with carcinoma of unknown primary site. Cancer 94:840–846

    Article  PubMed  CAS  Google Scholar 

  16. Saghatchian M, Fizazi K, Borel C et al (2001) carcinoma of unknown primary site: A chemotherapy strategy based on histological differentiation — results of a prospective study. Ann Oncol 12:535–540

    Article  PubMed  CAS  Google Scholar 

  17. Lortholary A, Culine S, Bouzy J et al (2002) Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of an unknown primary (CUP): results of a randomized phase II study. Proc Am Soc Clin Oncol 21:153a (abstr 609)

    Google Scholar 

  18. Palmeri S, Lorusso V, Palmeri L et al; Carcinomas of Unknown Primary Italian Study Group (2006) Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site: results of an Italian multicenter, randomized, phase II study. Cancer 107:2898–2905

    Article  PubMed  CAS  Google Scholar 

  19. Hainsworth JD, Spigel DR, Litchy S, Greco FA (2006) Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. J Clin Oncol 24:3548–3554

    Article  PubMed  CAS  Google Scholar 

  20. El-Rayes BF, Shields AF, Zalupski M et al (2005) A phase II study of carboplatin and paclitaxel in adenocarcinoma of unknown primary. Am J Clin Oncol 28:152–156

    Article  PubMed  Google Scholar 

  21. Greco FA, Erland JB, Morrissey LH et al (2000) Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol 11:211–215

    Article  PubMed  CAS  Google Scholar 

  22. Rebattu P, Quantin X, Ardiet C et al (2001) Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer. Lung Cancer 33:277–287

    Article  PubMed  CAS  Google Scholar 

  23. Stathopoulus GP, Mavroudis D, Tsavaris N et al (2001) Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for pancreatic cancer. Ann Oncol 12:101–103

    Article  Google Scholar 

  24. Alberts SR, Townley PM, Goldberg RM et al (2002) Gemcitabine and oxaliplatin for patients with advanced or metastatic pancreatic cancer: a North Central Cancer Treatment Group Phase I Study. Ann Oncol 13:553–557

    Article  PubMed  CAS  Google Scholar 

  25. Faivre S, Le Chevalier T, Monnerat C et al (2002) Phase I–II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma. Ann Oncol 13:1479–1489

    Article  PubMed  CAS  Google Scholar 

  26. André T, Tournigand C, Rosmordue O et al (2004) Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma (ABTA): a GERCOR study. Ann Oncol 15:1339–1343

    Article  PubMed  Google Scholar 

  27. Motzer RJ, Rodriguez E, Reuter VE et al (1995) Molecular and cytogenic studies in the diagnosis of patients with midline carcinomas of unknown primary site. J Clin Oncol 13:274

    PubMed  CAS  Google Scholar 

  28. Ramaswamy S, Golub TR (2002) DNA microarrays in clinical oncology. J Clin Oncol 20:1932

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Oncology Unit, University Hospital La Fe, Avda. Campanar, 21, ES-46009, Valencia, Spain

    J. Ponce Lorenzo, A. Segura Huerta, R. Díaz Beveridge, A. Giménez Ortiz, F. Aparisi Aparisi, T. Fleitas Kanonnikoff, P. Richart Aznar, H. de la Cueva Sapiña & J. Montalar Salcedo

Authors
  1. J. Ponce Lorenzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Segura Huerta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Díaz Beveridge
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Giménez Ortiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F. Aparisi Aparisi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T. Fleitas Kanonnikoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P. Richart Aznar
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. H. de la Cueva Sapiña
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J. Montalar Salcedo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Ponce Lorenzo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ponce Lorenzo, J., Segura Huerta, A., Díaz Beveridge, R. et al. Carcinoma of unknown primary site: development in a single institution of a prognostic model based on clinical and serum variables. Clin Transl Oncol 9, 452–458 (2007). https://doi.org/10.1007/s12094-007-0084-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-007-0084-6

Key words

Search

Navigation